Brief: Peptidream Announces Preclinical Results Demonstrating Efficacy Of Oral Myostatin Inhibitors In Preventing Loss Of Lean Mass Associated With Semaglutide Treatment
12/12/2024 13:05
Dec 12 (Reuters) - PeptiDream 4587.T :
* PEPTIDREAM ANNOUNCES PRECLINICAL RESULTS DEMONSTRATING
EFFICACY
OF ORAL MYOSTATIN INHIBITORS IN PREVENTING LOSS OF LEAN MASS
ASSOCIATED WITH SEMAGLUTIDE TREATMENT
* PEPTIDREAM INC - DISCOVERS POTENT MYOSTATIN INHIBITORS
* PEPTIDREAM INC - REPORTS SIGNIFICANT IMPROVEMENTS IN DMD
MICE
MODELS
Source text: ID:nBwbMJnRna
Further company coverage: 4587.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PeptiDream
See all newsTable: Peptidream 6-MTH group results (IFRS)
Brief: Peptidream Inc. - Initiation Of Phase 1 Clinical Trial By Novartis Marks Milestone For Peptidream
Brief: PeptiDream Announces First Dosing Of 64cu-Pd-29,875 In Gastric Cancer Patients
Table: Peptidream -Q1 group results (IFRS)
Brief: Peptidream Announces The Initiation Of Phase 1 Clinical Trial By Its Collaboration Partner